Censavudine
| Code | Size | Price |
|---|
| TAR-T30791-5mg | 5mg | £484.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T30791-50mg | 50mg | £2,119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T30791-100mg | 100mg | £3,275.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Censavudine( OBP-601, BMS-986001,festinavir,) is an inhibitor of nucleoside reverse transcriptase that is active against HIV resistance to both abacavir and tenofovir.
CAS:
634907-30-5
Formula:
C12H12N2O4
Molecular Weight:
248.238
Purity:
0.98
SMILES:
Cc1cn([C@@H]2O[C@](CO)(C=C2)C#C)c(=O)[nH]c1=O
References
1. Gupta SK, McComsey GA, Lombaard J, Echevarr?a J, Orrell C, Avihingsanon A, Osiyemi O, Santoscoy M, Ray N, Stock DA, Joshi SR, Hanna GJ, Lataillade M. Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. Lancet HIV. 2016 Jan;3(1):e13-22. doi: 10.1016/S2352-3018(15)00231-3. Epub 2015 Dec 12. PubMed PMID: 26762988.
2. Smith RA, Raugi DN, Wu VH, Leong SS, Parker KM, Oakes MK, Sow PS, Ba S, Seydi M, Gottlieb GS. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1. Antimicrob Agents Chemother. 2015 Dec;59(12):7437-46. doi: 10.1128/AAC.01326-15. Epub 2015 Sep 21. PubMed PMID: 26392486; PubMed Central PMCID: PMC4649195.
3. Yuan L, Schuster A, Shen JX, Garrison-Borowski P, Aubry AF. Dried blood spot analysis without dilution: Application to the LC-MS/MS determination of BMS-986001 in rat dried blood spot. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:201-9. doi: 10.1016/j.jchromb.2015.08.029. Epub 2015 Aug 28. PubMed PMID: 26340763.
4. Ortiz A, Benkovics T, Beutner GL, Shi Z, Bultman M, Nye J, Sfouggatakis C, Kronenthal DR. Scalable Synthesis of the Potent HIV Inhibitor BMS-986001 by Non-Enzymatic Dynamic Kinetic Asymmetric Transformation (DYKAT). Angew Chem Int Ed Engl. 2015 Jun 8;54(24):7185-8. doi: 10.1002/anie.201502290. Epub 2015 Apr 29. PubMed PMID: 25925234.